Mustang Bio Announces Pricing of $4 Million Public Offering

Rhea-AI Summary

Mustang Bio, Inc. announced a public offering of 16,877,638 shares of common stock, along with warrants, at a combined price of $0.237 per share to raise approximately $4 million. The offering is expected to close on May 2, 2024, with H.C. Wainwright & Co. as the placement agent. The proceeds will be used for working capital and general corporate purposes.

Positive

• Proceeds from the offering will provide additional working capital for Mustang Bio, Inc.

• The Company's focus on developing cell and gene therapies for difficult-to-treat cancers and rare genetic diseases shows a commitment to innovative medical solutions.

Negative

• The pricing of the shares at $0.237 per share could indicate a potential dilution for existing shareholders.

• Issuing additional shares and warrants may lead to downward pressure on the stock price in the short term.

Insights

Financial Analyst

Mustang Bio's decision to price their public offering at $0.237 per share and the accompanying warrants at the same exercise price is a strategic move aimed at raising capital, which could be indicative of the company's current cash flow needs. The offering size of $4 million is relatively small for a biopharmaceutical company, which suggests that this could be a bridge financing round designed to fund ongoing operations or specific projects until the company can secure more substantial funding. From an investor's perspective, the deep discount on the exercise price of the new warrants relative to the previous $1.58 suggests a dilution of value for current shareholders. However, the capital infusion might be necessary to continue the company's clinical programs or to prepare for commercialization activities. Investors should be aware of the potential for stock dilution and consider whether the company's future growth prospects justify this dilution.

Biotech Market Analyst

In the biotech industry, offerings like this are common as companies often burn through cash quickly due to the high costs associated with research and development, especially in the cell and gene therapy space. Mustang Bio's focus on treatments for cancers and rare genetic diseases is a high-risk but potentially high-reward area, meaning that any progress or setbacks in clinical trials could significantly affect the company's stock price and future financing needs. Investors should monitor the development pipeline and upcoming milestones, which can provide better insight into the potential return on investment. The expirations of the different series of warrants might indicate the company's own projections about when they expect meaningful developments or regulatory approvals could occur.

Securities & Exchange Law Expert

The offering is being conducted under a Form S-1 registration statement, which is a standard procedure for public offerings and allows the company to provide investors with detailed information about the offering and its business. The SEC's role in declaring the registration statement effective is important in ensuring that all material information is disclosed, providing transparency and protection for investors. The amendment to the existing warrants is also a significant point that should be scrutinized by investors. It is essential to examine the terms of these amendments, as they may affect the potential value of the investment, considering factors like the reduced exercise price and the extended exercisability period. This could signal management's confidence in the company's prospects or a strategy to incentivize the exercise of the warrants, potentially providing the company with additional capital in the future.

WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the pricing of a public offering of an aggregate of 16,877,638 shares of its common stock (or common stock equivalents in lieu thereof), Series A-1 warrants to purchase up to 16,877,638 shares of common stock, Series A-2 warrants to purchase up to 16,877,638 shares of common stock and Series A-3 warrants to purchase up to 16,877,638 shares of common stock, at a combined public offering price of $0.237 per share (or per common stock equivalent in lieu thereof) and accompanying warrants. The warrants will have an exercise price of $0.237 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. The Series A-1 warrants will expire five years from the date of stockholder approval, the Series A-2 warrants will expire twenty-four months from the date of stockholder approval and the Series A-3 warrants will expire nine months from the date of stockholder approval. The closing of the offering is expected to occur on or about May 2, 2024, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be approximately $4 million. The Company intends to use the net proceeds from this offering for working capital and general corporate and other purposes.

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-278006), which was declared effective by the Securities and Exchange Commission (the “SEC”) on April 29, 2024. The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC’s website at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

The Company also has agreed to amend certain existing warrants to purchase up to an aggregate of 2,588,236 shares of common stock that were previously issued in October 2023 and have an exercise price of $1.58 per share such that the amended warrants will have a reduced exercise price of $0.237 per share effective upon the closing of the offering, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants and will expire five years from the date of stockholder approval.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Mustang Bio

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR-T therapies. Mustang’s common stock is registered under the Securities Exchange Act of 1934, as amended, and Mustang files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.mustangbio.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements, include, but are not limited to, statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, the anticipated use of proceeds therefrom and the receipt of stockholder approval, any statements relating to our workforce reduction and other alternatives, growth strategy and product development programs, including the timing of and our ability to make regulatory filings such as INDs and other applications and to obtain regulatory approvals for our product candidates, statements concerning the potential of therapies and product candidates and any other statements that are not historical facts. Actual events or results may differ materially from those described herein due to a number of risks and uncertainties. Risks and uncertainties include, among other things, risks related to the satisfaction of the conditions necessary to transfer the lease of the Company’s manufacturing facility and receive the contingent payment in connection with the Company’s sale of its manufacturing facility in the anticipated timeframe or at all; whether the purchaser of the Company’s manufacturing facility is able to successfully perform its obligation to produce the Company’s products under the manufacturing services agreement on a timely basis and to acceptable standards; disruption from the sale of the Company’s manufacturing facility making it more difficult to maintain business and operational relationships; negative effects of the announcement or the consummation of the transaction on the market price of the Company’s common stock; significant transaction costs; the development stage of the Company’s primary product candidates, our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; the ability to execute on strategic or other alternatives; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by applicable law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contacts:
Jaclyn Jaffe and Nicole McCloskey
Mustang Bio, Inc.
(781) 652-4500
ir@mustangbio.com

 

FAQ

What is the purpose of Mustang Bio, Inc.'s public offering?

Mustang Bio, Inc. is conducting a public offering to raise funds for working capital and general corporate purposes.

How many shares are being offered in Mustang Bio, Inc.'s public offering?

Mustang Bio, Inc. is offering 16,877,638 shares of its common stock in the public offering.

Who is serving as the placement agent for Mustang Bio, Inc.'s public offering?

H.C. Wainwright & Co. is acting as the exclusive placement agent for Mustang Bio, Inc.'s public offering.

What is the expected closing date of Mustang Bio, Inc.'s public offering?

The public offering is expected to close on or about May 2, 2024, subject to customary closing conditions.

What will the net proceeds from Mustang Bio, Inc.'s public offering be used for?

The net proceeds from the public offering will be used for working capital and general corporate purposes.